Seres Therapeutics (STU:1S90) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1S90 Seres Therapeutics Inc STU:1S90
25 GF Score
Price €4.05
GF Value €64.04
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Seres Therapeutics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:1S90
25GF Score
Seres Therapeutics Inc STU:1S90
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Seres Therapeutics (STU:1S90) Overvalued in 2026?

Based on GuruFocus' analysis, Seres Therapeutics stock appears to be undervalued. The current stock price of €4.05 is trading 93.7% below its estimated GF Value™ of €64.04. GuruFocus considers Seres Therapeutics to be Possible Value Trap.

Key valuation signals for STU:1S90:

  • Dividends Received:
  • GF Value™: €64.04 vs. price of €4.05 (93.7% below fair value)
  • GF Score™: 25/100 with 5 warning signs

No single metric tells the full story. See the STU:1S90 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Seres Therapeutics Business Description

Other Exchanges MCRB:USA
Address 101 Cambridgepark Drive, Cambridge, MA, USA, 02140
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
25GF Score

Get the complete analysis for STU:1S90

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.05
Price
€64.04
GF Value